Categories: Wire Stories

Australia CBD Market Report 2020: How Would the Recent Proposal to Change the Scheduling for CBD Affect your Business? – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Australia CBD Sector: How Would the Recent Proposal to Change the Scheduling for CBD Affect your Business?” report has been added to ResearchAndMarkets.com’s offering.

CBD is listed on the Controlled Drug Register in Australia, which means that it can’t be sold as a consumer product.

From June 2021, the Therapeutic Goods Administration has enabled access to such products through pharmacies, and without a prescription. This report provides a detailed overview of the current regulatory regime in place in Australia for these products, covering everything from the hemp plant itself to extracts and finished products.

A proposal has been put forward that would change the scheduling of CBD, which in turn has a number of consequences. If this, and the Australian market in general, interests you then this is the report for you.

It not only provides information on the current regulatory regime for hemp and CBD in Australia, but it also offers analysis and data about the near future, as well as insight into the current status of medical and recreational cannabis.

Key Topics Covered:

Executive summary

  • Hemp plant
  • The hemp plant definition
  • Cultivation
  • Strains

THC

  • Requirements to grow
  • Disposal
  • Processing
  • Extracts as finished products
  • CBD isolates
  • Full/broad spectrum
  • Flowers

Finished products containing CBD and extracts

  • Food
  • Cosmetic products
  • Vaping products
  • Pet food
  • Import/export

Hemp

  • CBD isolates and full spectrum
  • Finished products

Medical cannabis

  • Access to cannabis-based medicinal products
  • Production of medical cannabis (high THC plants/flowers)
  • Near future

Recreational cannabis

Relevant laws

  • Relevant bodies

For more information about this report visit https://www.researchandmarkets.com/r/vywtbi

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Alex

Recent Posts

Fabrinet Announces Third Quarter Fiscal Year 2024 Financial Results

Exceeds Guidance Ranges with Record Revenue and Net Income Per Share BANGKOK--(BUSINESS WIRE)--Fabrinet (NYSE: FN),…

2 hours ago

South Korea Data Center Market Investment Analysis Report 2024-2029: Opportunities in IT, Electrical, Mechanical Infrastructure, General Construction, and Tier Standards – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "South Korea Data Center Market - Investment Analysis & Growth Opportunities 2024-2029" report…

5 hours ago

Revitalized “Marco Polo” Opera Celebrates Sino-Italian Ties at Guangzhou Opera House

GUANGZHOU, China--(BUSINESS WIRE)--On May 3rd and 4th, the Guangzhou Opera House welcomed nearly 200 international…

6 hours ago

BrainChip Earns Australian Patent for Improved Spiking Neural Network

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first…

6 hours ago

NetApp Appoints Market Growth and Revenue Operations Leader, Dallas Olson to Chief Commercial Officer Role

SAN JOSE, Calif.--(BUSINESS WIRE)--NetApp (NASDAQ: NTAP), the intelligent data infrastructure company, today announced Dallas Olson…

7 hours ago

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

BEIJING--(BUSINESS WIRE)--#Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on…

8 hours ago